r/trakstocks

- Slacker Radio's 4 million members will have to access to new program

- Tapping into the booming global audiobook market, valued at $5B and projected to reach $42B by 2031

- LiveOne now boasts 3 pillars of audio: music, podcasts, and audiobooks

LOS ANGELES, Aug. 16, 2024 (GLOBE NEWSWIRE) -- LiveOne, Inc. (NASDAQ: LVO), a leader in digital broadcasting and personalized entertainment, is excited to announce a strategic collaboration with Legible Inc. (CSE: READ) (OTCQB: LEBGF) (FSE: D0T), a premier digital reading and audiobook platform. This partnership is set to expand LiveOne’s Slacker Radio member base by offering enhanced value through exclusive access to Legible’s audiobook content.

Beginning in August, LiveOne’s Slacker Radio over 4 million members, will gain free access to a 'Book of the Month' audiobook, carefully curated by Legible’s team of experts. This initiative not only enriches the listening experience for Slacker Radio members but also seamlessly blends music with storytelling, creating a unique entertainment offering.

Bradley Konkol, Head of Slacker Radio for LiveOne, expressed his enthusiasm for the partnership: "At LiveOne, we're always looking for innovative ways to elevate our members' experience. Our collaboration with Legible introduces a fantastic mix of music and audiobooks, allowing our users to explore new content and enjoy a more diverse listening experience."

This collaboration is also aligned with LiveOne’s broader strategy to increase member engagement and retention. By offering a free audiobook each month and exclusive previews of Legible’s diverse audiobook catalog, LiveOne not only adds significant value to its membership but also fosters a deeper connection with its audience.

Key Benefits for LiveOne Members:

• Free 'Book of the Month' Audiobook: Each month, members will have access to a full-length audiobook, handpicked by Legible’s curators, at no additional cost.

• Exclusive Previews: Slacker Radio members can enjoy previews from a wide selection of audiobooks, allowing them to discover new authors and genres that align with their interests.

• Diverse Content: With a broad range of genres including fiction, non-fiction, mystery, and self-help, this partnership ensures that Slacker Radio members can enjoy a rich and varied audio experience.

In addition to enhancing member value, this collaboration positions LiveOne as a pioneer in the integration of music and audiobooks, driving increased engagement and attracting new members. By combining the strengths of both companies, this partnership is expected to contribute to LiveOne’s ongoing growth and success in the digital entertainment landscape.

About LiveOne and Slacker Radio Slacker Radio, a leading internet radio service owned by LiveOne, Inc., offers personalized music and entertainment streaming to millions of users. With expertly curated stations and customizable playlists, Slacker Radio delivers an unmatched listening experience.

About LiveOne, Inc. Headquartered in Los Angeles, California, LiveOne, Inc. (NASDAQ: LVO) is an award-winning, creator-first music, entertainment, and technology platform. The company delivers premium content worldwide through memberships, live, and virtual events. LiveOne’s subsidiaries include Slacker Radio and PodcastOne, which generate significant engagement across their platforms. LiveOne is available on multiple devices and platforms, providing a comprehensive entertainment experience for its global audience.

For more information about LiveOne, visit .

About Legible Inc.

Legible is a mobile-centric global company specializing in eBooks and audiobook entertainment, boasting a market opportunity exceeding billions of dollars. Legible’s extensive partnerships encompass four of the Big 5 Publishers and the world's largest eBook distributor, enabling Legible to seamlessly deliver millions of eBooks and audiobooks, effectively transforming any smart device into a dynamic library and eBookstore. At the heart of Legible’s innovation lies its LibrarianAI, the world's pioneering AI-powered literary assistant, enhancing the reading experience. Legible’s publishing division is revolutionizing the industry by crafting proprietary AI-enriched multimedia books, setting new standards in literary engagement. Legible is at the forefront of reshaping the digital publishing landscape, committed to gaining a significant market share by providing innovative 21st-century publishing solutions and enriching global reading experiences. Please visit Legible.com and discover the place where eBooks come to life.

~LiveOne IR Contact~**:**
Liviakis Financial Communications, Inc.
(415) 389-4670

~Press Contact~**:**
LiveOne

Phase III clinical trial is evaluating RenovoGem™ for the treatment of Locally Advanced Pancreatic Cancer

UNMC opened enrollment of TIGeR-PaC in June 2024 and joins esteemed clinical sites throughout United States participating in the study

LOS ALTOS, CA – August 14, 2024 – . (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a clinical-stage biopharmaceutical company developing novel precision oncology therapies based on a local drug-delivery platform, announced today that the first patient has been enrolled at the University of Nebraska Medical Center (“UNMC”) in RenovoRx’s ongoing pivotal Phase III TIGeR-PaC clinical trial for Locally Advanced Pancreatic Cancer (LAPC).

The TIGeR-PaC study is using RenovoRx’s TAMP™ (Trans-Arterial Micro-Perfusion) therapy platform, to evaluate the Company’s first product candidate, RenovoGem, which is a drug-device combination that utilizes pressure-mediated delivery of gemcitabine (chemotherapy) across the arterial wall near the tumor site to bathe the target tumor.  The study is comparing treatment with TAMP in LAPC to the current standard-of-care (systemic intravenous chemotherapy).

“Pancreatic cancer is aggressive, and difficult to detect and treat,” said Associate Professor at UNMC, Kelsey Klute, MD, Division of Oncology & Hematology Gastrointestinal Cancer, Pancreatic Cancer. “Chemotherapy given intravenously is the current standard treatment for most patients with pancreatic cancer. One of the biggest challenges in treating pancreatic cancer is that the tumor cells build a thick layer of scar tissue around the tumor, and this scar tissue makes it difficult for drugs to penetrate the tumor itself. I think this is one of the reasons that many investigational drugs tested in pancreatic cancer fail – they simply aren’t reaching the tumor at high enough concentration to have an effect. The ongoing TIGeR-PaC study is evaluating RenovoRx’s innovative targeted (intra-arterial) approach to chemotherapy delivery, which aims to deliver medicine theoretically through the layer of scar tissue directly to the tumor in the pancreas. We are hopeful that this approach will lead to better outcomes for our patients: both improved survival as well as decreased side effects. With this initial enrollment since launching our participation in the study at UNMC just a little over a month ago, I am encouraged by the interest in this important study at UNMC.”

“We are excited that UNMC has begun enrollment with their first patient in our ongoing Phase III TIGeR-PaC clinical trial,” said Leesa Gentry, Chief Clinical Officer of RenovoRx. “UNMC is the most recent clinical site to join our pivotal TIGeR-PaC clinical study. We believe UNMC will help drive enrollment of the TIGeR-PaC trial to completion next year because they treat a larger number of patients diagnosed with pancreatic cancer.  We are proud to collaborate with them as they strive to provide best-in-class care and share our deep commitment to improving outcomes for patients diagnosed with difficult-to-treat tumors, like pancreatic cancer.”

UNMC is the most recent clinical trial site to join the Phase III TIGeR-PaC study. The mission of the College of Medicine at the University of Nebraska Medical Center is to lead the world in transforming lives to create a healthy future for all individuals and communities through premier educational programs, innovative research, and extraordinary patient care.

The TIGeR-PaC clinical trial is currently enrolling unresectable LAPC patients at several sites across the US. To learn more about the study and the participating clinical trial sites, visit  (NCT03257033).

About the TIGeR-PaC Clinical Trial

TIGeR-PaC is an ongoing Phase III randomized multi-center study evaluating the proprietary TAMP™ (Trans-Arterial Micro-Perfusion) therapy platform for the treatment of Locally Advanced Pancreatic Cancer (LAPC.)  RenovoRx’s first product candidate using the TAMP technology, RenovoGem™, is a novel investigational oncology drug-delivery combination utilizing the Company’s FDA-cleared RenovoCath® device for the intra-arterial administration of chemotherapy, gemcitabine.

The first interim analysis in the Phase III clinical trial was completed in March 2023, with the Data Monitoring Committee recommending a continuation of the study. The TIGeR-PaC study is investigating TAMP in LAPC. The study’s primary endpoint is a 6-month Overall Survival benefit with secondary endpoints including reduced side effects versus standard of care. The second interim analysis for this study will be triggered by the 52nd event, which is estimated to occur in late 2024.

About Locally Advanced Pancreatic Cancer (LAPC)

According to the American Cancer Society’s Cancer Facts & Figures 2024 and PanCAN, respectively, pancreatic cancer has a 5-year all stages combined relative survival rate of 13% (Stages I-IV) and is on track to be the second leading cause of cancer-related deaths before 2030. LAPC is diagnosed when the disease has not spread far beyond the pancreas, however, has advanced to the point where it cannot be surgically removed. LAPC is typically associated with patients in Stage 3 of the disease as determined by the TNM (tumor, nodes and metastasis) grading system.

About RenovoRx, Inc.

RenovoRx is a clinical-stage biopharmaceutical company developing novel precision oncology therapies based on a local drug delivery platform for high unmet medical need with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx’s patented Trans-Arterial Micro-Perfusion (TAMP™) therapy platform is designed to ensure precise therapeutic delivery to directly target the tumor while potentially minimizing a therapy’s toxicities versus systemic intravenous therapy. RenovoRx’s novel and patented approach to targeted treatment offers the potential for increased safety, tolerance, and improved efficacy. Our Phase III lead product candidate, RenovoGem™, a novel oncology drug-device combination product, is being investigated under a U.S. investigational new drug application that is regulated by the FDA’s 21 CFR 312 pathway. RenovoGem is currently being evaluated for the treatment of locally advanced pancreatic cancer (LAPC) by the Center for Drug Evaluation and Research (the drug division of FDA). RenovoGem utilizes RenovoCath®, the Company’s FDA-cleared drug-delivery device, indicated for temporary vessel occlusion in applications including arteriography, preoperative occlusion, and chemotherapeutic drug infusion.

RenovoRx is also actively exploring the use of TAMP to treat cancers beyond LAPC as well as other commercialization strategies for its technology.

RenovoRx is committed to transforming the lives of patients by delivering innovative solutions to change the current paradigm of cancer care. RenovoGem is currently under investigation for TAMP therapeutic delivery of gemcitabine and has not been approved for commercial sale.

For more information, visit . Follow RenovoRx on , , and .